|
|
| Molecule |
Crofelemer has been in-licensed by Glenmark from Napo Pharmaceuticals, USA
|
| Indication |
HIV associated Diarrhoea, Adult acute infectious diarrhoea |
| Highlights |
| |
|
Currently undergoing Phase III trials in the US |
| |
|
Glenmark expects launch of Crofelemer in Developing countries by 2011 including India
|
| |
|
Currently undergoing Phase II trialsfor adult infectious diarrhoea in India |
| |
|
Glenmark has Crofelemer rights for Diarrhoea indications in 140 countries |
| |
|
Crofelemer granted fast track designation by the US-FDA
|
|
| Market Opportunity |
| |
|
ROW opportunity is around USD 80 mn for HIV
associated Diarrhoea |
|
|